Latest / GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News
Novo Says Women Lost 25% on CagriSema in Trial Analysis, With Differences by Menopause Stage
Novo Nordisk says women in its phase 3 REDEFINE 1 trial lost 25.0% of their body weight on average after 68 weeks on its investigational weekly injection CagriSema (cagrilintide plus semaglutide), compared with 3.0% on placebo, in a post hoc analysis presented at The Menopause Society 2026 Annual Meeting in San Diego. A second analysis grouped 1,902 women by menopausal stage: average weight loss was 26.7% in premenopausal, 24.8% in perimenopausal and 23.1% in postmenopausal women, versus about 2% on placebo. Both figures use the efficacy estimand, which assumes everyone stayed on treatment…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.